Cargando…

Beyond DNA Repair: Additional Functions of PARP-1 in Cancer

Poly(ADP-ribose) polymerases (PARPs) are DNA-dependent nuclear enzymes that transfer negatively charged ADP-ribose moieties from cellular nicotinamide-adenine-dinucleotide (NAD(+)) to a variety of protein substrates, altering protein–protein and protein-DNA interactions. The most studied of these en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weaver, Alice N., Yang, Eddy S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841914/ https://www.ncbi.nlm.nih.gov/pubmed/24350055 http://dx.doi.org/10.3389/fonc.2013.00290

Ejemplares similares

PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?
por: Swindall, Amanda F., et al.
Publicado: (2013)

Beyond DNA repair: the novel immunological potential of PARP inhibitors
por: Chabanon, Roman M., et al.
Publicado: (2019)

Top1-PARP1 association and beyond: from DNA topology to break repair
por: Chowdhuri, Srijita Paul, et al.
Publicado: (2021)

Functional Aspects of PARP1 in DNA Repair and Transcription
por: Ko, Hui Ling, et al.
Publicado: (2012)

Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
por: Clark, Curtis A., et al.
Publicado: (2021)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma
por: Weaver, Alice N., et al.
Publicado: (2015)

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics
por: Richard, Iain A., et al.
Publicado: (2022)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway
por: Jiang, Lingxiang, et al.
Publicado: (2022)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

PARP‐1 regulates DNA repair factor availability
por: Schiewer, Matthew J, et al.
Publicado: (2018)

Metnase and EEPD1: DNA Repair Functions and Potential Targets in Cancer Therapy
por: Nickoloff, Jac A., et al.
Publicado: (2022)

Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy
por: Heske, Christine M.
Publicado: (2020)

Editorial: Targeting DNA repair and the DNA damage response: Beyond the standard PI3 kinase-like kinases
por: Turchi, John J., et al.
Publicado: (2022)

Successes and Challenges of PARP Inhibitors in Cancer Therapy
por: Ricks, Tiffany K., et al.
Publicado: (2015)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity
por: Horton, Julie K., et al.
Publicado: (2013)

The HSF1–PARP13–PARP1 complex facilitates DNA repair and promotes mammary tumorigenesis
por: Fujimoto, Mitsuaki, et al.
Publicado: (2017)

The role of PARP in DNA repair and its therapeutic exploitation
por: Javle, M, et al.
Publicado: (2011)

Editorial: Inhibiting PARP as a Strategic Target in Cancer
por: Zorn, Kristin K., et al.
Publicado: (2016)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets
por: Shah, Girish M., et al.
Publicado: (2013)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation
por: Zhao, Wenxiu, et al.
Publicado: (2021)

DNA Damage, Repair, and Cancer Metabolism
por: Turgeon, Marc-Olivier, et al.
Publicado: (2018)

PARP1 recruits DNA translocases to restrain DNA replication and facilitate DNA repair
por: Ho, Yen-Chih, et al.
Publicado: (2022)

Structural Implications for Selective Targeting of PARPs
por: Steffen, Jamin D., et al.
Publicado: (2013)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation
por: Marquez, Stefanie B., et al.
Publicado: (2015)

PARP1pred: a web server for screening the bioactivity of inhibitors against DNA repair enzyme PARP-1
por: Lerksuthirat, Tassanee, et al.
Publicado: (2023)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

DNA repair mechanisms in cancer development and therapy
por: Torgovnick, Alessandro, et al.
Publicado: (2015)

Acetylation and Deacetylation of DNA Repair Proteins in Cancers
por: Li, Shiqin, et al.
Publicado: (2020)

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
por: Reinbolt, Raquel E., et al.
Publicado: (2013)

PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage
por: Das, Benu Brata, et al.
Publicado: (2014)

Inhibition of DNA damage repair by artificial activation of PARP with siDNA
por: Croset, Amelie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q3mhkufk1odcs4ore0jbo9q0ei